sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Cisatracurium

Medicine

Cisatracurium

Cisatracurium besylate injection is indicated: as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age to provide skeletal muscle relaxation in adults during…

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age
  • to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU
  • to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older
Do not take if
  • Cisatracurium Besylate Injection is contraindicated in patients with known hypersensitivity to cisatracurium. Severe anaphylactic reactions to Cisatracurium Besylate Injection have been reported.
  • The use of 10 mL Cisatracurium Besylate Injection multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol.

What it is used for

Cisatracurium Besylate Injection is indicated:

  • as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age
  • to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU
  • to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older

Who should not take it

  • Cisatracurium Besylate Injection is contraindicated in patients with known hypersensitivity to cisatracurium. Severe anaphylactic reactions to Cisatracurium Besylate Injection have been reported.
  • The use of 10 mL Cisatracurium Besylate Injection multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol.

Storing it

Storage

Cisatracurium Besylate Injection, USP should be refrigerated at 2°C to 8°C (36°F to 46°F) in the tray to preserve potency. Protect from light. DO NOT FREEZE. Upon removal from refrigeration to room temperature storage conditions (25°C/77°F), use Cisatracurium Besylate Injection, USP within 21 days even if re-refrigerated.

The container closure is not made with natural rubber latex.

The brand names mentioned in this document are the trademarks of their respective owners.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Cisatracurium; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/cisatracurium

APA 7th

sofidex. (2026, August 2). Cisatracurium. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/cisatracurium

AMA 11th

Cisatracurium. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/cisatracurium

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.